Literature DB >> 31313376

Controlling false discovery proportion in identification of drug-related adverse events from multiple system organ classes.

Xianming Tan1, Guanghan F Liu2, Donglin Zeng1, William Wang2, Guoqing Diao3, Joseph F Heyse2, Joseph G Ibrahim1.   

Abstract

Analyzing safety data from clinical trials to detect safety signals worth further examination involves testing multiple hypotheses, one for each observed adverse event (AE) type. There exists certain hierarchical structure for these hypotheses due to the classification of the AEs into system organ classes, and these AEs are also likely correlated. Many approaches have been proposed to identify safety signals under the multiple testing framework and tried to achieve control of false discovery rate (FDR). The FDR control concerns the expectation of the false discovery proportion (FDP). In practice, the control of the actual random variable FDP could be more relevant and has recently drawn much attention. In this paper, we proposed a two-stage procedure for safety signal detection with direct control of FDP, through a permutation-based approach for screening groups of AEs and a permutation-based approach of constructing simultaneous upper bounds for false discovery proportion. Our simulation studies showed that this new approach has controlled FDP. We demonstrate our approach using data sets derived from a drug clinical trial.
© 2019 John Wiley & Sons, Ltd.

Entities:  

Keywords:  drug safety; false discovery proportion; hierarchical testing; multiplicity; permutation; signal detection; two-stage approach

Year:  2019        PMID: 31313376      PMCID: PMC6731544          DOI: 10.1002/sim.8304

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  6 in total

1.  False Discovery Rate Control With Groups.

Authors:  James X Hu; Hongyu Zhao; Harrison H Zhou
Journal:  J Am Stat Assoc       Date:  2010-09-01       Impact factor: 5.033

2.  Use of the false discovery rate for evaluating clinical safety data.

Authors:  Devan V Mehrotra; Joseph F Heyse
Journal:  Stat Methods Med Res       Date:  2004-06       Impact factor: 3.021

3.  Flagging clinical adverse experiences: reducing false discoveries without materially compromising power for detecting true signals.

Authors:  Devan V Mehrotra; Adeniyi J Adewale
Journal:  Stat Med       Date:  2012-03-13       Impact factor: 2.373

4.  Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives.

Authors:  Mark J van der Laan; Sandrine Dudoit; Katherine S Pollard
Journal:  Stat Appl Genet Mol Biol       Date:  2004-06-15

5.  Comparative analysis of two rates.

Authors:  O Miettinen; M Nurminen
Journal:  Stat Med       Date:  1985 Apr-Jun       Impact factor: 2.373

6.  Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder.

Authors:  Martin Keller; Stuart Montgomery; William Ball; Mary Morrison; Duane Snavely; Guanghan Liu; Richard Hargreaves; Jarmo Hietala; Christopher Lines; Katherine Beebe; Scott Reines
Journal:  Biol Psychiatry       Date:  2005-10-24       Impact factor: 13.382

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.